Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lithium cocrystal - Alzamend Neuro

Next Previous
Drug Profile

Lithium cocrystal - Alzamend Neuro

Alternative Names: AL-001-Alzamend Neuro; LiProSal; LiProSalTM; Lithium salicylate/L-proline cocrystal

Latest Information Update: 27 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of South Florida
  • Developer Alzamend Neuro
  • Class Alkali metals; Antidementias; Antidepressants; Antimanics; Antipsychotics; Light metals; Small molecules
  • Mechanism of Action Neuron modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Alzheimer's disease; Bipolar disorders; Major depressive disorder; Post-traumatic stress disorders

Most Recent Events

  • 19 Nov 2025 Alzamend Neuro and Massachusetts General Hospital completes the clinical portion of a phase II trial in Alzheimer's disease, Bipolar disorders, Major depressive disorder, Post-traumatic stress disorders (In volunteers) in USA (PO)
  • 16 Jun 2025 Alzamend Neuro plans a phase IIa clinical trial for Alzheimer’s disease in the fourth quarter of 2025
  • 31 May 2025 Phase-II clinical trials in Bipolar disorders (In volunteers) in USA (PO) (Alzamend Neuro pipeline, July 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top